Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Similar documents
Pharmacodynamics & Pharmacokinetics 1

Lippincott Questions Pharmacology

PHARMACOKINETICS SMALL GROUP I:

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Pharmacotherapy Issues in the Pediatric Population

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

BASIC PHARMACOKINETICS

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Multiple IV Bolus Dose Administration

PHA5128 Dose Optimization II Case Study I Spring 2013

Pharmacokinetics Overview

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

General Principles of Pharmacology and Toxicology

Name: UFID: PHA Exam 2. Spring 2013

Industrial Toxicology

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

INTRODUCTION TO PHARMACOKINETICS

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Determination of bioavailability

Medication use in children

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

Posology. Posology and Dosage Regimen: Factors Affecting Drug Dosage: 08/09/ ) Age: 1. Young s Rule, based on age:

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

Understand the physiological determinants of extent and rate of absorption

BIOPHARMACEUTICS and CLINICAL PHARMACY

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Biology of Aging. Faculty Disclosure. Learning Objectives. I have no relevant financial disclosures relative to the content of this presentation.

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

Variation in drug responses & Drug-Drug Interactions

Pharmacokinetic parameters: Halflife

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Nonlinear Pharmacokinetics

Basic Concepts of TDM

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Introduction to Pharmacokinetics

Aging Changes That Impact Medication Management

Pharmacokinetics: The Basics

Drug dosing in Extremes of Weight

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Pharmacology in the Elderly

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Tala Saleh. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

Pharmacokinetics in pediatric population

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.

Potential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Pharmacokinetics. Karim Rafaat

AMINOGLYCOSIDES TDM D O N E B Y

Renal Excretion of Drugs

PHA Final Exam Fall 2001

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

DIF: COGNITIVE LEVEL: Understanding (Comprehension) REF: p. 37 TOP: NURSING PROCESS: General MSC: NCLEX: Health Promotion and Maintenance

Biomath M263 Clinical Pharmacology

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

Considerations for Sterile Compounding of Parenteral Products for Pediatric Use: Part 1 PharMEDium Lunch and Learn Series LUNCH AND LEARN

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

A REVIEW ON DOSAGE REGIMEN

One-Compartment Open Model: Intravenous Bolus Administration:

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

PHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84

PHA First Exam Fall 2003

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Basic pharmacokinetics. Frédérique Servin APHP hôpital Bichat Paris, FRANCE

Section 5.2: Pharmacokinetic properties

PHAR 7632 Chapter 16

Principles of Pharmacology. Pharmacokinetics & Pharmacodynamics. Mr. D.Raju, M.pharm, Lecturer PHL-358-PHARMACOLOGY AND THERAPEUTICS-I

Prescribing Drugs to the Elderly

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Environmental Variability

Are We Safely Dosing Medications in Obese Children? Geisinger Health System Bloomsburg University School of Nurse Anesthesia Kasie Worley, SRNA

Click to edit Master title style

TDM. Measurement techniques used to determine cyclosporine level include:

DEFINITIONS. Pharmacokinetics. Pharmacodynamics. The process by which a drug is absorbed, distributed, metabolized and eliminated by the body

Introducing Pharmacokinetics and Pharmacodynamics. Janice Davies Pharmacist Room 23 Maudland Building

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

Based on the information in the official labeling, please answer the following:

A Layperson s Guide to Pediatric Formulation Development

Chloroform Codeine Ether

ADME Issues in Children: Pediatric Pharmacokinetics

Model Answer B.Pharm. VII sem, Examination 2013 Biopharmaceutics and Pharmacokinetics Paper code: AS-2532

Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND

Transcription:

PCTH 325 Pharmacokinetics Dr. Shabbits jennifer.shabbits@ubc.ca September 12, 2013 Learning Objectives 1. Interpret Concentration vs graphs and use them to calculate half life and predict drug concentration 2. Describe the significance of steady state and how it is estimated 3. Describe the factors that contribute to variability in drug response between patients 4. Describe the key pharmacokinetic differences between neonates, the elderly and adults 5. Describe the main considerations related to pediatric drug dosing [Drug] in blood Concentration time relationships The ADME processes can be graphically represented on a concentration vs time graph used to determine or predict the plasma concentration of free drug A D IV any other route M + E Administer drug Take blood samples at various times Measure [drug] in blood Plot data The concentration-time equation iv Concentration C t = C 0 e -kt C 0 C t C t = drug conc at time t C 0 = drug conc at time 0 k = elimination rate constant the fraction of drug eliminated per unit time 0 0 t 1

lnc 0 Linearizing the concentration-time equation Exponential: C t = C 0 e -kt Logarithm: lnc t = -k t + lnc 0 ln Concentration (ln C t ) (t) Y = m X + b Slope = -k Application of k: Half-life Elimination half-life (t ½ ): the amount of time required for drug concentration to decrease by one half t ½ = 0.693 k Sample Calculation: The first order elimination rate constant for acetaminophen (Tylenol ) is 0.23 hr -1. What is its t ½? t ½ = 0.693 = 0.693 = 3 hours k 0.23 hr -1 * Note the units ~ k: time -1 vs t ½ : time Application of k: Drug elimination Application of the conc - time equation # Elimination half-lives % Drug Remaining % Drug Eliminated 0 100 0 1 50 50 2 25 75 3 12.5 87.5 4 6.25 93.75 5 3.13 96.87 Application: Estimating drug washout prior to surgery, following a drug overdose etc. ~5 half-lives for drug to be completely eliminated If the initial plasma concentration of Tylenol is found to be 20 μg/ml, what will the plasma concentration be after 8 hours? Use C t = C 0 e -kt or lnc t = -k t + lnc 0 Step 1: lnc 8h = -kt + lnc 0 Step 2: lnc 8h = -(0.23hr -1 )(8hr) + ln(20μg/ml) Step 3: lnc 8h = 1.16 Step 4: C 8h = 3.2 μg/ml 2

Drug accumulation steady state Repeated drug administration results in drug accumulation that eventually reaches a steady state plateau. Drug accumulation steady state The time to steady state depends on the drug s t ½ Rule of Thumb: it takes ~5 half-lives to achieve a steady state drug concentration (C SS ) Drug input Drug output Concentration Multiple Doses Steady State Absorption = Elimination (rate in = rate out) Single Dose # Elimination half-lives % C SS Reached 0 0 1 50 2 75 3 87.5 4 94 5 97 Therapeutic range The goal of drug therapy is to ensure that C SS falls within the therapeutic range Summary Administration of agonist or antagonist Toxic Level THERAPEUTIC RANGE po, sl, im iv protein binding, V d Concentration Therapeutic Level phase I and II, induction, inhibition k, t ½ Free drug binds receptor Response solubility, ph, ionization undesirable desirable 3

Variability in drug response Why do some drugs work for some people and not others? Why do people experience side effects differently? Should everyone take the same medication dose? Patient compliance Did the patient take the right amount of drug at the right time? was the Rx filled? (97% acute vs 40% long term prevention) forgetfulness / dementia complicated regimen / instructions not understood physical disability (ex: arthritis) lack of insight (schizophrenia, depression) side effects (optimized dosing?) economic factors (generic alternative?) Colour matters A survey of 600 people showed that medication colour affects compliance ~ International Journal of Biotechnology women prefer red men prefer pink pink = sweet yellow = salty white and blue = bitter orange = sour Patient compliance Did the patient take the right amount of drug at the right time? was the Rx filled? (97% acute vs 40% long term prevention) forgetfulness / dementia complicated regimen / instructions not understood physical disability (ex: arthritis) lack of insight (schizophrenia, depression) side effects (optimized dosing?) economic factors (generic alternative?) 4

Drug interactions Was the medication affected by other drugs or diet? P450 enzymes grapefruit juice alcohol Tums Genetics and Race : Pharmacogenomics t½ = poor response t½ = toxicity Genetics and Race: Acetaldehyde dehydrogenase involved in ethanol metabolism reduced or absent activity in Asians Age Are there differences between age groups? clinically important differences in both the young and old many relate to the ADME processes # of Subjects Drug conc (g/ml) 5

Age the elderly It s all downhill after 30... 7-fold in drug toxicity as one ages from 20 79 (3% in 20-29 group vs 21% in 70-79 group) Definitions of Old young old: old old: 65 84 years 85 years age-based estimates complicated by: limited clinical trial data physiological age chronological age multiple illnesses & medications interactions altered PK processes % Function Remaining Age (years) Absorption Distribution Oral delivery: gastric ph (geriatric = 4 vs adults = 2) how might this affect drug absorption in the stomach? (*consider both acids and bases) how will this affect drugs that are normally degraded by stomach acid? Notable differences in body composition: adipose tissue lipophilic drugs have a lower plasma concentration for equivalent dose TBW hydrophilic drugs have a higher plasma concentration for equivalent dose serum albumin fraction of free drugs that normally bind plasma proteins 6

Metabolism Notable differences in liver mass and function: liver mass liver blood flow Phase I enzyme activity in drug half-life (geriatric vs adult) need to dose or dosing frequency Phase II reactions (conjugation) are largely unchanged with advanced age Excretion Overall decrease in kidney function: 20% reduction in kidney size 30% fewer functioning glomeruli 35% fewer nephrons 40-50% reduction in blood flow in drug half-life (geriatric vs adult) need to dose or dosing frequency Age the young Neonatal pharmacokinetics Perinate: Neonate: Infant: Child: Adolescent: Adult: 20 weeks gestation 27 days birth 27 days 28 days 11 months 1 11 years 12 17 years > 17 years Pediatrics does not deal with miniature men and women, with the same disease and reduced doses in smaller bodies Dr. Abraham Jacobi Key PK differences between neonates and adults body composition and the ADME processes Little clinical data on drug safety in infants and children Most drugs used off label with dosages based on experience and observation not experimental evidence 7

Absorption Oral delivery: gastric ph (pediatric = 4 vs adults = 2) how will this affect drug absorption in the stomach? (*consider both acids and bases) how will this affect drugs that are normally degraded by stomach acid? Distribution Body Composition (as % body weight) Total body water Neonate Adult 80 60 Protein 10 20 Vd of hydrophilic drugs in neonate free fraction of protein bound drugs in neonate Fat 10 (term) 1-3 (preterm) 20 How would the [plasma] of a drug with Vd = 200 L change in the neonate? Metabolism Decrease in drug metabolism due to immaturity of some Phase I & II enzymes need to dose or dosing frequency Enzyme System Expression Excretion Elimination of renally excreted drugs decreased in the neonate due to reduced GFR and renal tubular secretion (only ~20% that of adult for 1 st year) t ½ (neonate vs adult) Phase I Cyp 3A7 & 4A1 Cyp 2D6 & 2E1 Cyp 3A4 & 2C family at birth hours after birth first few weeks Ampicillin Gentamicin 4 hr vs 1-2 hr 18 hr vs 2 hr need to dose or frequency Phase II Cyp 1A2 Glucuronyl transferase ~ 3 months several months premature infants << renal function vs full-term 8

Pediatric drug dosing Medication errors in neonates can have severe consequences the most pharmacologically vulnerable stage of life Optimal dosing based on: plasma [drug] > body surface area > weight > age but NOT adult dose corrected for weight Summary factors affecting drug response Compliance Drug interactions Disease Ethnicity Age young and old all ADME processes potentially affected Start low and go slow When in doubt check it out 9